Slide 1: MedCap Investor in Life Science, May 2022
aQ, MO P MEDCAP INVESTOR IN LIFE SCIENCE May 2022
Slide 2: We create value in Life Science
We create value in Life Science 2
Slide 3: MedCap | An active investor in Life Science companies
MedCap | An active investor in Life Science companies MedTech Business Area Specialty Pharma Business Area Sales by Segment (MSEK) Geographies Employees 7% 363 Sweden 34% 26% 956 42% Nordic Europe 66% Listed on Stockholm RoW Nasdaq Mid Cap 25% MedTech Specialty Pharma 3
Slide 4: Sales and EBITDA rolling 12 months by quarter
Sales and EBITDA rolling 12 months by quarter MSEK (Net sales) MSEK (EBITDA) / % 1 100 Sales CAGR: 12% 250 1 000 EBITDA CAGR: 29% 956 916 885 900 858 817 834 218 801 200 786 800 757 763 203 726 739 734 699 709 186 700 672 639 171 596 166 150 600 564 155 157 525 540 147 504 508 513 140 141 500 466 12
Slide 5: Highlights Q1
Highlights Q1 • Sales growth by 18% Q1 R12 • EBITDA increased by 39% Net Sales • All companies in both business areas, MedTech +18% +15% growth and Specialty Pharma, contributed to growth • Profitability driven by volume growth EBITDA +39% +31% • Price increases partially offset growth • Long lead-t
Slide 6: Contributing to an equal society
2021 Highlights Contributing to an equal society; Tender products that leads to better health and inclusion in society renewals Product launches 6
Slide 7: Streamlined workflow with digital ECG
2021 Highlights | Streamlined workflow with digital ECG Product launches Broader ‘go to market’ A C O M P L E T E D I G I TA L S O L U T I O N W I T H I N E C G ECG ECG MANAGEMENT VA C U U M S YS T E M & SYSTEMS SYSTEM ELECTRODES 7
Slide 8: Packaging Solutions / Nutrition
2021 Highlights | Packaging Solutions Nutrition Growth Profitability growth 8
Slide 9: Multi-Ply | Carbon Fibre Manufacturer for Medical
2021 Highlights Multi-Ply | Carbon Fibre Manufacturer for Medical New OEM customer Setting up OEM Partnerships + Engineering & Manufacturing Expertise New Facility to Improve Operations and Capacity for Growth 9
Slide 10: Specialty Pharma
2021 Highlights Product launches Out- Specialty Pharma licensing Building the registered specialty pharma portfolio • Business Development R12 MSEK • Registered Pharmaceuticals (own and partner products) 120,0 23% top 8 (R12 months) • Non-Licensed pharmaceuticals 100,0 • Extemporaneous formulations
Slide 11: Financial Targets
Financial Targets Net sales in 2-3 years Annual EBITDA growth Net debt / EBITDA 1,500 MSEK >15% <3x 11
Slide 12: Investment strategy
Investment strategy Investment criteria What we look for in a company Life Science Small and mid-sized MedTech, Specialty Pharma (<25 mEUR) Clear value proposition Value creation journey Market fundamentals Scalable business Life science M&A possibilities ESG Innovative Majority Long-term PEOPLE Own
Slide 13: Why invest in MedCap?
Why invest in MedCap? 1 2 3 4 Important Industry Profitable Growth Proven Model Large & Growing Market Life Science industry Annual growth of 12% over Decentralized model – Fragmented market – many improves quality of life the last 5 years customer oriented small and medium sized life responsibility
Slide 14: Thank You! Q&A
Thank You ! Q&A Anders Dahlberg Kristina Ekblad CEO CFO anders.dahlberg@medcap.se kristina.ekblad@medcap.se +46 704 269 262 +46 703 322 167 14